Ehlers-Danlos Syndrome (EDS): A Complete Guide

Ehlers-Danlos syndrome (EDS) is a group of 13 inherited connective tissue disorders, defined in the 2017 international classification, in which faulty collagen weakens the joints, skin, blood vessels and internal organs. Hypermobile EDS (hEDS) is by far the most common type and the only one without a known gene, so it is diagnosed clinically with the 2017 criteria rather than with a genetic test, according to Malfait and colleagues (2017).

What Is Ehlers-Danlos Syndrome?

Ehlers-Danlos Syndrome is a group of genetic connective tissue disorders that affect the body’s collagen. Collagen is the most abundant protein in the human body. It is the structural scaffolding in skin, joints, blood vessels, organs, and bones. When collagen is faulty, the effects ripple through nearly every system.

Think of collagen as the glue and framework that holds the body together. In EDS, that framework is stretched, weakened, or structurally altered. Joints move beyond their normal range. Skin may be unusually soft and stretchy. Blood vessels and organs may be more fragile. The severity varies enormously, from people with mild hypermobility and occasional joint pain to individuals with life-threatening vascular complications.

EDS has been recognized in medical literature for over a century, named after Edvard Ehlers and Henri-Alexandre Danlos who described the condition in the early 1900s. Yet it remains dramatically underdiagnosed. The current estimated prevalence for all types of EDS combined is approximately 1 in 2,500 to 1 in 5,000, though some researchers believe hypermobile EDS specifically may be far more common than these figures suggest ^[1].

Clinicians and patients use several names for the same group of conditions. The formal plural is "the Ehlers-Danlos syndromes," and older texts use numbered types: hEDS was once called EDS type III or EDS hypermobility type, and vascular EDS was EDS type IV. Joint hypermobility syndrome (JHS) was an older label that now largely maps to hEDS or hypermobility spectrum disorder (HSD) ^[2].

Types of Ehlers-Danlos Syndrome

The 2017 International Classification identifies 13 subtypes of EDS, each with distinct clinical features and, in most cases, an identified genetic cause. Here are the most clinically relevant types.

Hypermobile EDS (hEDS)

By far the most common type, hEDS is the only subtype without an identified causative gene as of the latest research. It is diagnosed clinically based on a set of criteria (discussed below). Features include generalized joint hypermobility, chronic musculoskeletal pain, recurrent joint subluxations or dislocations, and a range of systemic symptoms including fatigue, GI dysfunction, and dysautonomia ^[2].

hEDS is inherited in an autosomal dominant pattern, meaning a person needs only one copy of the altered gene (once it is identified) to have the condition. Many patients can trace the trait through their family, though the severity can vary significantly between family members.

Classical EDS (cEDS)

Classical EDS is characterized by very stretchy, fragile skin that bruises easily and heals with widened, atrophic scars (often described as “cigarette paper” scars). Joint hypermobility is present but is often less of a focus than the skin involvement. cEDS is caused by mutations in the COL5A1 or COL5A2 genes and can be confirmed through genetic testing ^[3].

Vascular EDS (vEDS)

Vascular EDS is the most serious type of EDS. It is caused by mutations in the COL3A1 gene, affecting type III collagen found in blood vessels, the intestines, and the uterus. People with vEDS are at risk for spontaneous arterial rupture, organ rupture, and uterine rupture during pregnancy. The skin tends to be thin and translucent rather than stretchy. Joint hypermobility is typically limited to the small joints of the hands. Median life expectancy has historically been reduced, though modern surveillance and management are improving outcomes ^[4].

Genetic testing and genetic counseling are strongly recommended when vEDS is suspected, given the serious implications for medical management and family planning.

Kyphoscoliotic EDS (kEDS)

Kyphoscoliotic EDS is a rare autosomal recessive form characterized by severe muscle weakness at birth, progressive scoliosis, joint laxity, and skin fragility. It is caused by mutations in the PLOD1 or FKBP14 genes ^[5].

Other Types

Additional subtypes include arthrochalasia EDS, dermatosparaxis EDS, cardiac-valvular EDS, brittle cornea syndrome, spondylodysplastic EDS, musculocontractural EDS, myopathic EDS, and periodontal EDS. Each is rare and has specific genetic causes and clinical features ^[6].

How the Main EDS Types Compare

The main EDS types differ in which collagen is affected, which tissue is most at risk, and whether a genetic test can confirm the diagnosis. The table below summarizes the four types most patients and clinicians encounter, using the genes and features described in the 2017 classification ^[1].

The practical point is that a gene panel can confirm or rule out most EDS types, but it cannot confirm hEDS. A negative panel in someone with hypermobility and systemic symptoms therefore does not end the evaluation; it shifts it toward the clinical hEDS criteria and toward hypermobility spectrum disorder.

Hypermobile EDS in Detail

Because hEDS is the most common type and the one most patients and providers will encounter, it deserves a closer look.

Hypermobile EDS is a multisystem condition: joint hypermobility is its most visible sign, but chronic pain, fatigue, autonomic and gut symptoms often shape daily life more. The international consortium that wrote the 2017 criteria described hEDS as having a natural history that tends to move from hypermobility in childhood toward pain and stiffness in adulthood ^[8].

The Symptom Picture

hEDS is much more than “being flexible.” The joint hypermobility is just the most visible part of a systemic condition. Common symptoms include:

Musculoskeletal:

• Joint hypermobility affecting multiple joints
• Chronic, widespread musculoskeletal pain (often starting in childhood or adolescence)
• Recurrent joint subluxations (partial dislocations) and full dislocations, sometimes occurring with minimal force or during sleep
• Early-onset osteoarthritis due to joint instability
• Temporomandibular joint (TMJ) dysfunction
• Muscle spasms and myofascial pain
• Tendinopathy and bursitis

Skin and Tissue:

• Soft, velvety skin that may be mildly hyperextensible
• Easy bruising
• Slow or poor wound healing
• Stretch marks (striae) at a young age or without significant weight change
• Piezogenic papules (small herniations of fat through the heel fascia, visible when standing)

Systemic:

• Chronic fatigue that often does not improve with rest
• Gastrointestinal issues: reflux, bloating, gastroparesis, irritable bowel-type symptoms, constipation or diarrhea
• Dysautonomia symptoms (particularly POTS)
• Headaches and migraines
• Anxiety and mood disturbances (which may have both neurobiological and situational components)
• Bladder dysfunction
• Dental crowding and fragile dental enamel
• Eye involvement (myopia, dry eyes)

The 2017 Diagnostic Criteria for hEDS

In 2017, the International EDS Consortium published updated diagnostic criteria for hEDS, replacing the older Brighton criteria. The new criteria are more specific and consist of three parts, all of which must be met ^[2]:

Criterion 1: Generalized Joint Hypermobility (Beighton Score)

The Beighton score is a 9-point scoring system that assesses hypermobility at five sites:

1. Passive dorsiflexion of the 5th finger beyond 90 degrees (1 point each hand)
2. Passive opposition of the thumb to the forearm (1 point each hand)
3. Hyperextension of the elbow beyond 10 degrees (1 point each arm)
4. Hyperextension of the knee beyond 10 degrees (1 point each leg)
5. Forward flexion of the trunk with knees extended, palms flat on floor (1 point)

A positive Beighton score is 5 or more for adults up to age 50, and 4 or more for those over 50. For prepubertal children, the cutoff is 6 or more. Historical hypermobility can also be considered through a five-point questionnaire if the Beighton score is one point below the threshold ^[7].

Criterion 2: Must meet two or more of the following (Feature A, B, or C):

Feature A (5 or more of the following 12 systemic features):

• Unusually soft or velvety skin
• Mild skin hyperextensibility
• Unexplained striae
• Bilateral piezogenic papules
• Recurrent or multiple hernias
• Atrophic scarring at two or more sites
• Pelvic floor, rectal, or uterine prolapse without predisposing factors
• Dental crowding and high or narrow palate
• Arachnodactyly (long, slender fingers)
• Arm span to height ratio of 1.05 or greater
• Mitral valve prolapse based on echocardiogram
• Aortic root dilation with z-score greater than +2

Feature B: Positive family history of one or more first-degree relatives independently meeting the diagnostic criteria for hEDS.

Feature C: Musculoskeletal complications (must have at least one):

• Musculoskeletal pain in two or more limbs, daily for at least 3 months
• Chronic widespread pain for at least 3 months
• Recurrent joint dislocations or frank joint instability without trauma

Criterion 3: All of the following must be met:

• Absence of unusual skin fragility (which would suggest another EDS type)
• Exclusion of other heritable and acquired connective tissue disorders
• Exclusion of alternative diagnoses that could explain the symptoms

Genetics of EDS

One of the most frustrating aspects of hEDS for patients and researchers alike is the lack of an identified causative gene. For all other EDS subtypes, specific genetic mutations have been found, typically in genes that code for collagen or enzymes involved in collagen processing ^[3].

For hEDS, research is actively ongoing. Several candidate genes have been investigated, and it is likely that hEDS involves multiple genetic variants rather than a single gene mutation. The Hypermobile Ehlers-Danlos Genetic Evaluation (HEDGE) study and other large-scale genomic efforts are working to identify the genetic basis ^[8].

Key genetic points:

• cEDS: COL5A1, COL5A2, rarely COL1A1 mutations. Symoens and colleagues (2012) found type V collagen mutations in over 90% of patients with classic EDS ^[3].
• vEDS: COL3A1 mutations (occasionally COL1A1)
• kEDS: PLOD1 or FKBP14 mutations
• hEDS: Unknown; autosomal dominant inheritance pattern observed clinically
• Genetic testing is recommended for non-hEDS types to confirm diagnosis and guide management
• Genetic counseling is valuable for all EDS patients, especially those with vEDS or those planning families

Is Ehlers-Danlos syndrome inherited?

Most EDS types are inherited. Hypermobile, classical and vascular EDS follow an autosomal dominant pattern, so a parent with the condition has a 50% chance of passing it to each child. Kyphoscoliotic EDS and several rare types are autosomal recessive, which means both parents carry a variant and each child has a one in four chance of being affected. A genetic counselor can explain what a specific family history means.

The Diagnostic Path

Getting diagnosed with EDS, particularly hEDS, can be a long and frustrating process. Many patients see several different specialists over a period of years before receiving an accurate diagnosis. The condition is often mistaken for fibromyalgia, “growing pains” in children, anxiety, or simply dismissed as “you’re just flexible.”

Fibromyalgia is the most common mislabel because both conditions involve widespread pain and fatigue. The difference is that hEDS also shows measurable joint hypermobility and connective tissue signs on examination, which is why a Beighton score and skin examination belong in any workup for widespread chronic pain that started young. Our overview of fibromyalgia as a condition covers the other side of that comparison.

Who Can Diagnose EDS?

EDS can be diagnosed by geneticists (the gold standard, especially for non-hEDS types), rheumatologists, and some specially trained primary care providers and physical therapists. The key is finding a clinician who is familiar with the 2017 diagnostic criteria and the broader clinical picture.

What to Expect at a Diagnostic Evaluation

A diagnostic evaluation for EDS usually takes one long appointment, sometimes followed by genetic testing and referrals. The clinician typically works through these steps:

1. Detailed personal and family history
2. Beighton score assessment
3. Skin examination (texture, extensibility, scarring)
4. Assessment of systemic features
5. Review of musculoskeletal history (injuries, subluxations, pain patterns)
6. Screening for associated conditions
7. Genetic testing if a non-hEDS type is suspected

Bringing a written timeline of injuries, dislocations, surgeries and family members with similar problems makes the history portion faster and more accurate. Photos of skin scarring or of joints in hyperextended positions can help too. A step by step walkthrough is in our post on how an EDS diagnosis is made.

Hypermobility Spectrum Disorder (HSD)

Patients who have symptomatic joint hypermobility but do not meet the full 2017 criteria for hEDS may be diagnosed with Hypermobility Spectrum Disorder. HSD is not a “lesser” diagnosis. Patients with HSD can have symptoms just as severe as those with hEDS, and the treatment approach is the same. The distinction is primarily for research classification purposes ^[9].

Castori and colleagues (2017) describe HSD as a set of subgroups, such as generalized, peripheral, localized and historical HSD, depending on which joints are hypermobile ^[2]. In practice, the label matters less than the plan: both diagnoses lead to stability-focused physical therapy and screening for the same associated conditions.

Managing EDS

No current treatment corrects the underlying collagen defect in EDS. Management focuses on protecting joints, managing pain, treating associated conditions, and optimizing function and quality of life. Care is usually shared between a primary care physician, a physical therapist and specialists such as a rheumatologist, cardiologist, gastroenterologist or pain physician, depending on which systems are involved.

Physical Therapy: The Cornerstone

Physical therapy is the single most important intervention for EDS, but it must be the right kind of physical therapy. Standard PT approaches can actually make things worse if the therapist is not familiar with hypermobility.

Effective PT for EDS focuses on:

• Joint stabilization: Strengthening the muscles around hypermobile joints to provide the stability that ligaments and tendons cannot
• Proprioception training: People with EDS often have poor body awareness (proprioception), contributing to injuries. Balance work and proprioceptive exercises are essential
• Closed-chain exercises: Exercises where the hands or feet are fixed (wall push-ups, squats, planks) are generally safer than open-chain movements that allow joints to move through excessive range
• Low-impact strengthening: Pilates, aquatic therapy, and clinical yoga (with modifications) are often well-tolerated
• Core stability: A strong core helps protect the spine and improves overall stability
• Postural training: Many EDS patients develop compensatory posture patterns that contribute to pain

Red flags in PT for EDS: if a therapist pushes you to stretch more, emphasizes increasing flexibility, uses aggressive manual manipulation, or dismisses your pain, find a different therapist ^[10].

Pain Management

Chronic pain is one of the most debilitating aspects of EDS. Pain management often requires a multimodal approach:

• Physical approaches: Heat/cold therapy, TENS units, gentle massage, myofascial release
• Bracing and taping: Ring splints for finger joints, knee braces, ankle supports, kinesiology tape
• Medications: NSAIDs (short-term), muscle relaxants, low-dose tricyclic antidepressants, gabapentin or pregabalin for neuropathic pain, topical pain medications
• Interventional approaches: Prolotherapy, PRP injections, trigger point injections (results vary)
• Mind-body approaches: Pain neuroscience education, mindfulness-based stress reduction, biofeedback

For widespread chronic pain treatment in EDS, Chopra and colleagues (2017) recommend combining physical, pharmacological and psychological approaches rather than relying on any single drug, and they point out that pain in EDS has several sources at once: joints, muscles, nerves and the gut ^[11].

A note on opioids: while opioids are sometimes necessary for acute pain (such as after dislocations or surgery), long-term opioid use in EDS is generally discouraged due to the risk of dependence, hyperalgesia, and GI side effects that can worsen already-present gastroparesis and motility issues ^[11].

Pacing

Pacing is the practice of balancing activity and rest to avoid the boom-bust cycle that plagues many EDS patients. It means learning your limits, taking breaks before you are exhausted, and spreading activities throughout the day rather than pushing through and paying for it later.

Practical pacing strategies:

• Break tasks into smaller chunks with rest periods
• Alternate between different types of activities (sitting, standing, moving)
• Plan demanding activities for your best time of day
• Use assistive devices (shower chairs, grabbers, jar openers) to conserve energy
• Learn to say no without guilt

Joint Protection

• Avoid hyperextending joints, even if it feels natural
• Use proper body mechanics when lifting, carrying, and moving
• Wear supportive footwear (custom orthotics can help)
• Consider ergonomic modifications at work (standing desk adjustments, ergonomic keyboards, supportive chairs)
• Use ring splints (silver or thermoplastic designs) for finger joint instability
• Support joints during sleep with positioning pillows

Where PRP, Prolotherapy and Other Clinic Treatments Fit

Regenerative injections such as platelet-rich plasma (PRP) and prolotherapy are offered to some people with EDS for unstable or painful joints, but there are no controlled trials showing they help in EDS specifically. The 2017 international pain management review by Chopra and colleagues lists them as interventional options with variable results, not as standard care ^[11]. Most of these treatments are cash pay, and their use in EDS is off label.

What is the idea behind PRP and prolotherapy for hypermobile joints?

PRP concentrates platelets and growth factors from a patient’s own blood and injects them into a tendon, ligament or joint. Prolotherapy injects an irritant solution, usually dextrose, to provoke a local healing response that is meant to thicken lax ligaments. The rationale is plausible for a connective tissue disorder, but the research on both comes mostly from osteoarthritis and tendon injuries in people without EDS. The PRP treatment guide and the prolotherapy overview summarize what that research shows, and our comparison of prolotherapy and PRP covers how the two differ.

What should someone with EDS ask before an injection?

• Ask whether the clinician has treated patients with hEDS or HSD before, and how they adjust technique for fragile tissue and slower wound healing.
• Ask whether local anesthetic will be used, since local anesthetics may be less effective in EDS.
• Ask how the injection fits with a stability-focused physical therapy program, because injections without strengthening work have little rationale.
• Ask what outcome they will measure and when, so that you and the clinician can decide together whether to stop.

Anyone with suspected vascular EDS should avoid elective injections and procedures until the diagnosis is clarified with a geneticist, because tissue and vessel fragility changes the risk calculation.

How to read the clinic directory for EDS-related care

Regenerated.com lists clinics that offer treatments people with EDS ask about, including the national list of clinics offering PRP injections, biofeedback therapy providers for pain and autonomic symptoms, and IV hydration clinics that some people with POTS use alongside oral fluids. Listing order is not paid ranking. Featured slots are labeled and capped, Verified means the clinic completed credential checks rather than paid for placement, and the directory is free for patients. Inclusion in the directory is not an endorsement, and the guide to Featured, Verified and organic listings explains each label.

Associated Conditions

EDS, particularly hEDS, rarely travels alone. Screening for and treating associated conditions is a critical part of care.

POTS (Postural Orthostatic Tachycardia Syndrome)

Up to 50% of hEDS patients meet diagnostic criteria for POTS. The lax connective tissue in blood vessel walls may contribute to excessive venous pooling and poor autonomic compensation upon standing. Managing POTS through fluid/salt loading, compression garments, medications, and exercise reconditioning can significantly improve overall function ^[12].

De Wandele and colleagues (2014) found that people with hEDS reported more autonomic symptoms than controls and showed measurable differences on autonomic testing, which supports screening for orthostatic intolerance in anyone with hEDS who feels faint, foggy or racing when upright ^[12]. The POTS treatment guide covers the medication and non-drug options in detail, and our post on how EDS and POTS connect goes deeper into the overlap.

MCAS (Mast Cell Activation Syndrome)

An increasing number of hEDS patients are being identified with MCAS, a condition where mast cells release mediators (histamine, prostaglandins, leukotrienes) inappropriately. Symptoms can include flushing, hives, abdominal pain, diarrhea, brain fog, and anaphylactoid reactions. Treatment with antihistamines and mast cell stabilizers can provide relief for both the MCAS symptoms and some EDS-related complaints ^[13].

Seneviratne, Maitland and Afrin (2017) note that the evidence linking mast cell disorders to EDS is still early and based largely on case series, so MCAS should be diagnosed on its own criteria rather than assumed ^[13]. The combination of EDS, POTS and MCAS is common enough that it has its own discussion in our post on the MCAS, POTS and EDS triad.

Chiari Malformation and Craniocervical Instability

Some hEDS patients develop craniocervical instability (CCI), where the ligaments supporting the junction between the skull and the upper cervical spine become lax. This can lead to brainstem compression and is associated with Chiari malformation (where the cerebellar tonsils descend through the base of the skull). Symptoms can include severe headaches (especially with Valsalva), upper limb weakness, coordination problems, and swallowing difficulty. Upright MRI may be needed to detect positional instability ^[14].

Gastroparesis and GI Dysfunction

GI problems are extremely common in hEDS. Gastroparesis (delayed stomach emptying), functional dyspepsia, gastroesophageal reflux, and motility disorders throughout the GI tract can all occur. The connective tissue component of the GI tract is affected just like joints and skin. Management may include dietary modifications, prokinetic medications, and treatment of any coexisting MCAS ^[15].

TMJ Dysfunction

The temporomandibular joint is a common problem area in EDS. Jaw subluxation, clicking, locking, and pain are frequent complaints. Management includes jaw exercises, night guards, soft diet during flares, and avoiding wide mouth opening.

Jaw pain that persists despite these measures is worth a review by a dentist or oral surgeon who understands hypermobility, because aggressive jaw surgery carries more risk in fragile tissue. The temporomandibular joint disorder overview and the TMJ treatment options page describe the wider range of approaches.

Other overlapping conditions

Other conditions reported more often in hEDS include small fiber neuropathy, pelvic floor dysfunction, migraine, chronic fatigue and early osteoarthritis in unstable joints. Each needs its own workup, because treating the overlapping condition often improves day to day function more than any EDS-specific step. Readers dealing with widespread joint pain or chronic fatigue syndrome symptoms can use those pages to compare the patterns.

Exercise: What Works and What Doesn’t

Exercise is essential for EDS management, but the wrong type of exercise can cause real harm. Here is a practical breakdown.

Do’s

• Swimming and aquatic exercise: The water supports joints while providing resistance. Many EDS patients find they can exercise in water when land-based exercise is too painful.
• Pilates (with modifications): Focuses on core strength, controlled movement, and stability. A Pilates instructor familiar with hypermobility can modify exercises to avoid hyperextension.
• Recumbent cycling: Provides cardiovascular exercise without the impact of running or the balance challenges of upright cycling.
• Resistance training with controlled range of motion: Building muscle strength is protective. Focus on controlled movements, stopping before end range. Resistance bands and light weights are good starting points.
• Walking: Low-impact and accessible. Good footwear is essential.
• Tai chi and gentle yoga: Can improve balance, proprioception, and body awareness. Yoga must be heavily modified to avoid pushing into hypermobile ranges.

Don’ts

• Contact sports and high-impact activities: The risk of joint injury is high.
• Heavy overhead lifting without training: Shoulder instability is common in EDS, and overhead movements carry risk.
• Stretching into hypermobile ranges: You do not need to increase flexibility. In fact, stretching beyond your already-excessive range can destabilize joints further.
• Extreme or ballistic movements: Quick, forceful movements can cause subluxations.
• Running on hard surfaces: High impact combined with joint instability increases injury risk. If you run, trails or a treadmill may be gentler.

The golden rule: movement should build strength and stability around your joints, not increase your range of motion. If an exercise causes joint pain (not muscle soreness), modify or substitute it ^[10].

EDS and Pregnancy

Pregnancy in EDS requires careful planning and monitoring, but many people with hEDS have healthy pregnancies and deliveries. Key considerations include:

• Genetic counseling: EDS (all types) has genetic implications for offspring. In autosomal dominant conditions like hEDS, each child has a 50% chance of inheriting the condition.
• Increased joint instability: Pregnancy hormones (especially relaxin) increase ligament laxity, which can worsen instability in already-hypermobile joints.
• Preterm birth: Some studies suggest a moderately increased risk of preterm labor and premature rupture of membranes in hEDS ^[16].
• Anesthesia considerations: Local anesthetics may be less effective in EDS patients. This is important to communicate to your obstetric anesthesiologist for epidural planning.
• Wound healing: Cesarean incisions and episiotomies may heal more slowly.
• POTS management during pregnancy: Some POTS medications are not safe during pregnancy, and volume status must be carefully managed.
• Vascular EDS: Pregnancy carries significant risk in vEDS and should be managed at a specialized center with genetic counseling.

A high-risk OB familiar with connective tissue disorders is recommended for pregnant EDS patients.

Pezaro, Pearce and Reinhold (2021) reviewed hEDS in pregnancy and childbirth and concluded that outcomes vary widely, that research quality is limited, and that individualized care planning is more useful than blanket rules ^[16].

Does EDS Affect Life Expectancy?

Hypermobile and classical EDS are not generally associated with a shortened life expectancy. The main impact of hEDS is on pain, function and quality of life rather than survival. Vascular EDS is the exception, because arterial, bowel and uterine rupture can be fatal.

In the largest early cohort of vascular EDS, Pepin and colleagues (2000) reviewed 220 index patients and their relatives and reported a median survival of 48 years ^[4]. Care has changed since then: people with vEDS are now usually followed with regular arterial imaging, blood pressure control and emergency plans, and most experts advise avoiding elective surgery and invasive procedures where possible.

The rarer types each carry their own risks. Kyphoscoliotic EDS can affect breathing through spinal deformity and arterial fragility, and cardiac-valvular EDS can involve progressive valve disease ^[6]. A geneticist can explain what a specific subtype means for long-term monitoring.

Mental Health and EDS

Living with a chronic, often invisible, frequently dismissed illness takes a real toll on mental health. Research shows elevated rates of anxiety and depression in the EDS population, and these are not “all in your head” ^[17].

Several factors contribute:

• Neurobiological: Dysautonomia and mast cell mediators can directly affect brain chemistry and produce anxiety-like symptoms that are physiological, not psychological.
• Pain: Chronic pain is one of the strongest risk factors for depression.
• Diagnostic delay: Years of being dismissed or misdiagnosed causes medical trauma and erodes trust in healthcare systems.
• Loss and grief: Many EDS patients grieve the loss of activities, careers, or life plans that their condition has changed.
• Social isolation: Chronic illness can shrink social circles, especially when symptoms are unpredictable.

Effective mental health support for EDS patients includes therapists familiar with chronic illness, support groups (in person or online), pain psychology, and treating the underlying physical contributors (POTS, MCAS, untreated pain) that may be driving neurobiological anxiety and mood changes.

Baeza-Velasco and colleagues (2019) reviewed the cognitive, emotional and behavioral side of pain in hEDS and argued that psychological approaches such as cognitive behavioral therapy work best when they sit alongside physical treatment rather than replacing it ^[17]. Readers comparing options can start with the anxiety treatment guide and the depression treatment guide.

Finding an EDS-Knowledgeable Provider

Finding a provider who understands EDS can feel like searching for a needle in a haystack. Here are some strategies that work:

• The Ehlers-Danlos Society: Maintains a healthcare provider directory at ehlers-danlos.com
• Genetics clinics: Medical geneticists are often the most knowledgeable about EDS diagnosis and management
• Rheumatology: Some rheumatologists have developed EDS expertise, particularly those in academic settings
• Patient networks: EDS support groups and online communities are often the best source of local provider recommendations
• Multidisciplinary clinics: A few centers have developed EDS-specific clinics with coordinated care across specialties
• Telehealth options: Several EDS specialists offer telemedicine consultations, which can be valuable for patients in underserved areas

When evaluating a potential provider, ask whether they are familiar with the 2017 diagnostic criteria, whether they screen for associated conditions, and what their treatment philosophy is. A good EDS provider will take your symptoms seriously, look at the full clinical picture, and work with you to build a management plan.

Which specialists are involved in EDS care?

EDS care usually involves a team. A medical geneticist or rheumatologist confirms the diagnosis, a physical therapist with hypermobility experience leads the stability program, and a primary care physician coordinates. Depending on symptoms, the team can also include a cardiologist or autonomic specialist for POTS, an allergist or immunologist for MCAS, a gastroenterologist for dysmotility, a neurosurgeon for suspected craniocervical instability, a pain physician, a psychologist and, for vascular EDS, a vascular surgeon.

Integrative and regenerative clinics sometimes join that team for pain or autonomic symptoms. The questions that matter are the same as for any clinician: experience with hypermobility, willingness to coordinate with the rest of the team, and clear explanations of what the evidence does and does not show. Our guide to reading a city clinic page explains how listings, labels and filters work in the directory.

Living Well with EDS

A diagnosis of EDS can feel overwhelming, but it is also the starting point for getting the right care. Many patients describe the diagnosis itself as a turning point, not because anything changed physically, but because they finally had an explanation and a framework for treatment.

The core message bears repeating: EDS is a lifelong connective tissue condition, hypermobile EDS is diagnosed clinically with the 2017 criteria, and management rests on stability-focused physical therapy, pain management, pacing and treatment of associated conditions such as POTS and MCAS.

Key principles for thriving with EDS:

• Build a team of providers who understand connective tissue disorders
• Make physical therapy and joint-protective exercise a long-term habit, not a short-term fix
• Screen for and treat associated conditions (POTS, MCAS, GI dysfunction)
• Learn your body’s patterns and pace accordingly
• Connect with the EDS community for support, information, and advocacy
• Advocate for yourself in medical settings, and bring information when needed
• Address mental health proactively
• Stay informed about emerging research, as the EDS field is advancing rapidly

Related Reading

• POTS (Postural Orthostatic Tachycardia Syndrome): A Complete Guide
• Mast Cell Activation Syndrome (MCAS): What You Need to Know
• Understanding Dysautonomia: When Your Autonomic Nervous System Misfires
• Safe Exercise Strategies for Hypermobility

Frequently Asked Questions

Can Ehlers-Danlos Syndrome be fixed, or only managed?

No treatment corrects the collagen defect behind Ehlers-Danlos syndrome, so EDS is managed rather than resolved. Management centers on hypermobility-aware physical therapy, pain management, pacing, joint protection with braces or splints, and treatment of associated conditions such as POTS, MCAS and gastrointestinal dysmotility. Severity varies enormously between people, even within one family, so a good plan is individualized and adjusted over time with a team that understands connective tissue disorders.

How common is EDS and why does it take so long to diagnose?

Estimates for all types of EDS combined range from about 1 in 2,500 to 1 in 5,000 people, and hypermobile EDS is thought to be underdiagnosed. Diagnosis takes a long time because hEDS has no identified gene, so no blood or genetic test can confirm it, and its pain and fatigue are often mislabeled as fibromyalgia, anxiety or growing pains. Many patients see several specialists over years before someone applies the 2017 criteria.

How is hypermobile EDS diagnosed?

Hypermobile EDS is diagnosed clinically with the 2017 international criteria, and all three criteria must be met. Criterion 1 is a positive Beighton score: 5 or more for adults up to age 50, 4 or more over 50, and 6 or more for prepubertal children. Criterion 2 requires at least two of three features: systemic signs, family history or musculoskeletal complications. Criterion 3 requires ruling out other connective tissue disorders and alternative diagnoses.

Can physical therapy help, or could it make things worse?

Physical therapy helps most people with EDS when it builds stability rather than flexibility. Effective programs focus on joint stabilization, proprioception training, closed-chain exercises and core strength, according to Engelbert and colleagues (2017). Standard physical therapy can make symptoms worse if the therapist pushes stretching, uses aggressive manipulation or dismisses pain. Ask any new therapist about their experience with hypermobile EDS or hypermobility spectrum disorder before starting.

Are treatments like prolotherapy and PRP reliable for EDS?

Prolotherapy and PRP injections are not reliable treatments for EDS on current evidence. The 2017 international pain management review lists them among interventional options with variable results, and no controlled trials have tested them in people with EDS. Both are usually cash pay and off label for this use. Some people try them for one specific unstable or painful joint, ideally alongside stability-focused physical therapy and with a clinician experienced in hypermobility.

Are pain medications like opioids recommended for EDS?

Long-term opioid use is generally discouraged in EDS, although short courses may be needed after a dislocation or surgery. The concerns are dependence, opioid-induced hyperalgesia and gastrointestinal side effects that can worsen gastroparesis and slow motility, which are already common in hEDS. Chopra and colleagues (2017) favor a multimodal plan instead: bracing and taping, short-term NSAIDs, muscle relaxants, low-dose tricyclics, gabapentin or pregabalin, topical medications and mind-body techniques.

Sources

1. Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):8-26. doi:10.1002/ajmg.c.31552 ↩
2. Castori M, Tinkle B, Levy H, et al. A framework for the classification of joint hypermobility and related conditions. Am J Med Genet C Semin Med Genet. 2017;175(1):148-157. doi:10.1002/ajmg.c.31539 ↩
3. Symoens S, Syx D, Malfait F, et al. Comprehensive molecular analysis demonstrates type V collagen mutations in over 90% of patients with classic EDS. Hum Mutat. 2012;33(10):1485-1493. doi:10.1002/humu.22137 ↩
4. Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med. 2000;342(10):673-680. doi:10.1056/NEJM200003093421001 ↩
5. Yeowell HN, Walker LC. Mutations in the lysyl hydroxylase 1 gene that result in enzyme deficiency and the clinical phenotype of Ehlers-Danlos syndrome type VI. Mol Genet Metab. 2000;71(1-2):212-224. doi:10.1006/mgme.2000.3076 ↩
6. Brady AF, Demirdas S, Fournel-Gigleux S, et al. The Ehlers-Danlos syndromes, rare types. Am J Med Genet C Semin Med Genet. 2017;175(1):70-115. doi:10.1002/ajmg.c.31550 ↩
7. Juul-Kristensen B, Rogind H, Jensen DV, Remvig L. Inter-examiner reproducibility of tests and criteria for generalized joint hypermobility and benign joint hypermobility syndrome. Rheumatology (Oxford). 2007;46(12):1835-1841. doi:10.1093/rheumatology/kem290 ↩
8. Tinkle B, Castori M, Berglund B, et al. Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome type III and Ehlers-Danlos syndrome hypermobility type): clinical description and natural history. Am J Med Genet C Semin Med Genet. 2017;175(1):48-69. doi:10.1002/ajmg.c.31538 ↩
9. Castori M, Hakim A. Contemporary approach to joint hypermobility and related disorders. Curr Opin Pediatr. 2017;29(6):640-649. doi:10.1097/MOP.0000000000000541 ↩
10. Engelbert RH, Juul-Kristensen B, Pacey V, et al. The evidence-based rationale for physical therapy treatment of children, adolescents, and adults diagnosed with joint hypermobility syndrome/hypermobile Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet. 2017;175(1):158-167. doi:10.1002/ajmg.c.31545 ↩
11. Chopra P, Tinkle B, Hamonet C, et al. Pain management in the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):212-219. doi:10.1002/ajmg.c.31554 ↩
12. De Wandele I, Rombaut L, Ez-Ehani L, et al. Dysautonomia and its underlying mechanisms in the hypermobility type of Ehlers-Danlos syndrome. Semin Arthritis Rheum. 2014;44(1):93-100. doi:10.1016/j.semarthrit.2013.12.006 ↩
13. Seneviratne SL, Maitland A, Afrin L. Mast cell disorders in Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet. 2017;175(1):226-236. doi:10.1002/ajmg.c.31555 ↩
14. Henderson FC, Austin C, Benzel E, et al. Neurological and spinal manifestations of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):195-211. doi:10.1002/ajmg.c.31549 ↩
15. Fikree A, Chelimsky G, Collins H, et al. Gastrointestinal involvement in the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):181-187. doi:10.1002/ajmg.c.31546 ↩
16. Pezaro S, Pearce G, Reinhold E. Hypermobile Ehlers-Danlos syndrome during pregnancy, birth and beyond. BMC Pregnancy Childbirth. 2021;21:612. doi:10.1186/s12884-021-04092-7 ↩
17. Baeza-Velasco C, Bulbena A, Polanco-Carrasco R, Jaussaud R. Cognitive, emotional, and behavioral considerations for chronic pain management in the Ehlers-Danlos syndrome hypermobility-type: a narrative review. Disabil Rehabil. 2019;41(9):1110-1118. doi:10.1080/09638288.2017.1419294 ↩